Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin mechanisms in glucose metabolism using 75g OGTT with double-tracer
jRCTs031210600Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imeglimin in type 2 diabetes mellitus (T2DM), sponsored by Sumitomo Pharma. Primary endpoint: Change in AUC0-3h glucose during 75 g OGTT at 20 weeks. Started Jul 2022; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031210600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210600.